Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.54 |
| ▸ | F7 | P08709 | 5/20 | 0.54 |
| ▸ | F3 | P13726 | 5/20 | 0.54 |
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685319 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL289449 | 0.98 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL290199 | 0.98 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL289450 | 0.98 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL3699857 | 0.94 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL3699859 | 0.94 | ALDH1A1 (0.51) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL18944784 | 0.90 | PPARG (0.53) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL15930625 | 0.88 | ALDH1A1 (0.49) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL2784824 | 0.88 | ALDH1A1 (0.49) | ALDH1A1CYP19A1F7F3PPARG | |
| SCHEMBL3700269 | 0.88 | ALDH1A1 (0.49) | ALDH1A1CYP19A1F7F3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-08-07 | — | — | US | disclosed |
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-08-07 | — | — | US | disclosed |
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-08-07 | — | — | US | disclosed |
| US-8735436-B2 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-05-27 | — | — | US | disclosed |
| US-8735436-B2 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-05-27 | — | — | US | disclosed |
| US-8735436-B2 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-05-27 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
| WO-2010128401-A9 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-12-08 | — | — | WO | disclosed |
| WO-2010128401-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-11 | — | — | WO | disclosed |
| EP-2248798-A1 | Novel lipid compounds | Pronova BioPharma Norge AS (NO) | 2010-11-10 | — | — | EP | disclosed |
| EP-2248798-A1 | Novel lipid compounds | Pronova BioPharma Norge AS (NO) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | ALDH1A1 695/4885CYP19A1 1476/4885F7 1019/4885 |
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | ALDH1A1 663/4885CYP19A1 1451/4885F7 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.